3 assets in Malignant Testicular Leydig Cell Tumor

Therapeutic assets addressing Malignant Testicular Leydig Cell Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Malignant Testicular Leydig Cell Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Malignant Testicular Leydig Cell Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Malignant Testicular Leydig Cell Tumor	National Cancer Institute (NCI)	P2	CCC (53)